CCM DBio, PanGen set to launch biosimilars for kidney dialysis

CCM Duopharma Biotech Bhd (CCMDB) and PanGen Biotech, Inc. have completed their clinical trials for the biosimilar erythropoietin or EPO product which can be used in kidney dialysis.

Recombinant version of EPO is used as the therapeutic agent of all anemia patients, acute anemia in kidney dialysis patients, anemia due to anti-cancer chemotherapy and patients requiring blood transfusion.

CCMDB said through Duopharma’s investment into the RM18mil joint clinical trials, the latter obtained exclusive licence to package, fill & finish, and distribute the EPO product in Malaysia, Singapore and Brunei.

Start your ads-free experience now!

Monthly Plan


Annual Plan


Billed as RM148.00/year

1 month

Free Trial

For new subscribers only

Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

VS rewards shareholders with proposed 1-for-10 bonus issue of warrants
Systech partners with EISSB for AI data centers and solutions
Ringgit ends flat versus US dollar
Setting the stage for gig workers
Exploring fuel alternatives
Tengku Zafrul: Embrace AI to achieve significant productivity improvements
Is the market rally sustainable?
Sunway to acquire shares in Daiwa Sunway Development for RM25mil
Subsidy cuts a necessary ‘evil’
MBSB Bank committed to helping authorities nab syndicate

Others Also Read